🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "major milestone" in the fight against increasingly resistant strains of the bacteria, according to scientists.

A Global Challenge

The sexually transmitted infection are on the rise worldwide, with figures suggesting over 82 million infections per year. Notably increased rates are reported in the African continent and nations within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune development in the reality of increasing worldwide cases, the spread of superbugs and the highly restricted available drugs currently available.”

Public health authorities are deeply concerned about the rise in drug-resistant strains. The World Health Organization has classified it as a "high-priority threat". Recent surveillance showed that resistance to key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Therapies Receive Clearance

One new antibiotic, alternatively called Nuzolvence, was cleared by the US FDA in December for treating gonorrhoea. This disease can lead to significant complications, including infertility. Experts believe that targeted use of this new drug will help delay the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, gained clearance in close succession. This drug, which is additionally indicated for urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for medication research. The non-profit organisation GARDP partnered with the drug firm its industry partner to develop it.

“This authorization represents a major breakthrough in the therapy of highly resistant gonorrhoea, which until now has been outpacing medical innovation.”

Testing Results and Global Access

According to findings detailed in a major medical journal, zoliflodacin successfully treated over nine in ten of uncomplicated infections. This establishes an comparable level with the typical regimen, which combines two antibiotics. The research included over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Clinicians on the front lines have expressed optimism. Having a easy-to-administer therapy of this kind is described as a "game-changer" for managing the epidemic. This is considered essential to reduce the burden of the disease for patients and to stop the proliferation of extremely resistant gonorrhoea globally.